Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

Marc A Riedl1, Henriette Farkas1, Emel Aygören-Pürsün1

  • 1From the Division of Allergy and Immunology, University of California, San Diego, La Jolla (M.A.R.); the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary (H.F.); University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt (E.A.-P.), and the Institute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology, Berlin (M.M.) - all in Germany; Naval Hospital of Athens, Athens (F.P.); Asthma and Allergy Associates, Colorado Springs (D.F.S.), and IMMUNOe Research Center, Centennial (I.M.) - both in Colorado; Clinical Center of Allergology, Clinic of Allergy and Asthma, University Hospital Alexandrovska, Medical University of Sofia, Sofia, Bulgaria (M.S.); the Department of Systems Medicine, University of Padua, Padua (M.C.), and Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese, and Dipartimento di Scienze Biomediche per la salute, University of Milan, Milan (A.Z.) - all in Italy; Tel Aviv Sourasky Medical Center (D.H.) and Sheba Medical Center (N.A.-L.), Tel Aviv, and Bnai Zion Medical Center, Haifa (A.K.) - all in Israel; Chiba University Hospital, Chiba, Japan (D.H.); the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds (S.S.), and KalVista Pharmaceuticals, Salisbury (P.K.A., J.H., M.I., M.D.S., C.M.Y.) - both in the United Kingdom; Jagiellonian University Medical College, Krakow (M.S.), and Medical University of Lodz, Lodz (M.K.) - both in Poland; Icahn School of Medicine at Mount Sinai, New York (P.J.B.); Allergy and Clinical Immunology Department, Centro Hospitalar Universitário de S. João, and Faculty of Medicine, University of Porto, Porto, Portugal (E.D.); Marycliff Clinical Research, Spokane, WA (R.G.); Hospital Universitario Bellvitge de L'Hospitalet de Llobregat, Allergology Department, Barcelona (R.L.); University Clinic of Dermatology, School of Medicine, University Saints Cyril and Methodus, Skopje, North Macedonia (V.G.P.); Washington University School of Medicine, St. Louis (H.J.W.); KalVista Pharmaceuticals, Cambridge, MA (P.K.A., J.H., M.I., M.D.S., C.M.Y.); AARA Research Center, Dallas (W.R.L.); the University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati (J.A.B.); and the Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (D.M.C.).

Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
418
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
766
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
271